VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma

Glioblastoma Clinical Trial

Official title:

VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma to Examine Safety, Tolerability, Immune and Biomarker Response to the Investigational VEGFR-2 DNA Vaccine VXM01

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02718443
• Other study ID #: VXM01-02-DE
• Status: Completed
• Phase: Phase 1
• Start date: May 2016
• Est. completion date: July 2018

Study information

• Verified date: October 2018
• Source: Vaximm GmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

VXM01 phase I pilot study in patients with operable recurrence of a glioblastoma to examine safety, tolerability, immune and biomarker response to the investigational VEGFR-2 DNA vaccine VXM01

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: July 2018
• Est. primary completion date: August 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Written informed consent, signed and dated

2. Histologically diagnosed intracranial supratentorial malignant glioma (contrast-enhancing anaplastic astrocytoma WHO Grade III or glioblastoma WHO Grade IV).

3. Male or female patients who must be post-menopausal for at least 2 years or surgically sterile.

4. Age =18 years

5. Evidence of tumor progression following at least one therapy regimen that must have contained radiation and chemotherapy with temozolamid, as measured by MRI

6. Candidates for a tumor reoperation

7. Neurosurgical intervention should be postponable for 30 days

8. Laboratory results (clinical chemistry, hematology, urine, liver enzymes, creatinine) without clinically relevant abnormalities

9. Patients must be able to undergo MRI

10. No concomitant medication with dexamethasone at the time of vaccination

11. No active infection at the time of vaccination

12. Karnofsky performance status >70

13. Appropriate hematologic parameters (for immunomonitoring): leukocytes =4.0 x 109 / L, lymphocytes =0.6 x 109 / L

14. Tumor samples available for pathology review, central detection of T-cell responses in the peripheral blood and in the tumor tissue

15. No medical or social conditions that may interfere with study outcome and follow-up

Exclusion Criteria:

1. Treatment in any other clinical trial within 30 days before screening

2. Known positive test results for Hepatitis B surface antigen , hepatitis C virus antibodies, human immunodeficiency virus antibodies -1/-2

3. Any other condition or treatment that, in the opinion of the investigator, might interfere with the study or current drug or substance abuse

4. Inability to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study

5. Unlikely to comply with the protocol requirements, instructions and study-related restrictions; e.g., uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study

6. Pregnancy or breast feeding

7. Positive for anti-typhoid IgG/IgM antibodies according to the onsite test on Day 0

8. Cardiovascular disease defined as:

Uncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg)

Arterial thromboembolic event within 6 months before randomization including:

• Myocardial infarction

• Unstable angina pectoris

• Cerebrovascular accident

• Transient ischemic attack

9. Congestive heart failure New York Heart Association grade III to IV

10. Serious ventricular arrhythmia requiring medication

11. Clinically significant peripheral artery disease > grade 2b according to Fontaine

12. Intracranial ischemic stroke within 6 months before randomization

13. History of intracranial hemorrhage

14. Hemoptysis within 6 months before randomization

15. Esophageal varices

16. Upper or lower gastrointestinal bleeding within 6 months before inclusion (Day 0)

17. Significant traumatic injury or surgery within 4 weeks before randomization

18. Non-healing wound, incomplete wound healing, bone fracture or any history of gastrointestinal ulcers within three years before inclusion, or positive gastroscopy within 3 months before inclusion

19. Gastrointestinal fistula

20. Thrombolysis therapy within 4 weeks before randomization

21. Presence of any acute or chronic systemic infection

22. Major surgical procedures, or open biopsy within 4 weeks before randomization

23. Chronic concurrent therapy within 2 weeks before and during the treatment period up to Day 35 with:

• Corticosteroids (except steroids for adrenal failure or emesis prophylaxis up to 4 mg daily dose) or immunosuppressive agents

• Antibiotics

• Bevacizumab

• Any cancer anti-angiogenic treatment

24. Chemotherapy from screening until reoperation (Day 35)

25. Known multi-drug resistant gram-negative germ

26. History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the study results or render the patient at high risk for treatment complications

27. Women of childbearing potential

28. Any condition which results in an undue risk for the patient during the study participation according to the investigator

Related Conditions & MeSH terms

• Glioblastoma
• Recurrence

Intervention

Drug:
• VXM01
Oral immunotherapy targeting VEGFR2

Locations

Country	Name	City	State
Germany	Neurology Clinic and National Center for Tumor Diseases	Heidelberg

Sponsors (1)

Lead Sponsor	Collaborator
Vaximm GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability taking into account treatment-limiting toxicities (TLTs)	AEs listed together with information on onset, duration, severity, seriousness, relationship to the study drug, relationship to chemotherapy and to the underlying disease, outcome, and action taken. Frequency tables by System Organ Class and preferred term.	12 months
Secondary	Immune Response by Enzyme Linked Immuno Spot (ELISpot)	Patient-individual VEGFR-2 specific T cell responses will be determined by ELISpot using cryopreserved peripheral blood mononuclear cells	12 months
Secondary	Serum biomarker Response by Enzyme Linked Immuno Sorbent Assay (ELISA)	Biomarkers including VEGF A and Collagen IV determined from periphaeral blood samples	12 months
Secondary	Vascular normalization index (VNI) including tumor perfusion acc. to Sorensen 2009	Determined by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) (ktrans), dynamic susceptibility contrast imaging (DSC), blood volume maps (cerebral blood volume [CBV] of smaller vessels) and collagen IV	12 months
Secondary	Tumor immune cell infiltration by tumor tissue immunohistochemistry	Tumor tissue immunohistochemistry staining including Evaluations of effector T cell infiltration, regulatory T-cells (Treg), myeloid derived suppressor cells (MDSC)	35 days
Secondary	Tumor response or progression on MRI acc. to Response Assessment in Neuro-Oncology (RANO) criteria	MRI comprising the National Brain Tumor Society /EORTC protocol for gliomas	12 months
Secondary	Clinical Response including time to progression, progression free survival, overall survival		12 months
Secondary	Biodistribution and shedding of VXM01 bacteria	Bacterial vector tissue biodistribution, persistence, and shedding of viable Ty21a bacteria (VXM01) determined by cultivation of stool samples	10 days